HOLLYWOOD, Fla. and PRINCETON, N.J., Oct. 15 /PRNewswire/ -- Azopharma Product Development Group, LLC, a leader in preclinical and pharmaceutical product development services and PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, are pleased to announce the completion of a business development and co-promotion alliance to leverage complementary services, develop business opportunities, and jointly manage projects for certain services provided by the two companies.
Phil Meeks, chief executive officer, Azopharma Product Development Group commented “This agreement is an exciting opportunity for both of our organizations. Both companies will be introduced to new sets of clients and the clients will be exposed to new compelling solutions for their early phase development.”
Jeffrey P. McMullen, president and chief executive officer, PharmaNet Development Group agrees, “PharmaNet’s and Azopharma’s services complement each other. Azopharma is an established provider of in vivo services with pre-clinical and toxicology capabilities and our bioanalytical capabilities are ideally positioned to support these studies.”
About Azopharma Product Development Group, LLC
Azopharma Product Development Group, The Total Product Development Company(TM) is FDA registered, DEA approved and client audited on a regular basis. In product development, it comes down to the right people, their commitment and application of experience. Partnering with Azopharma provides customers with the confidence of assured success. We welcome visits to our South Florida facilities as well as our other sites to conduct audits or meet with our pharmaceutical scientists to outline a study that meets your specific needs. Contact us at development@azopdogroup.com.
About PharmaNet Development Group, Inc.
PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and 43 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit their website at www.pharmanet.com.
SOURCE PharmaNet Development Group, Inc.; Azopharma Product Development Group, LLC
CONTACT: Phil Meeks of Azopharma Product Development Group, LLC,
+1-954-433-7480, development@azopharma.com, or Anne-Marie Hess of PharmaNet
Development Group, Inc., +1-609-951-6842, ahess@pharmanet.com
Web site: http://www.pharmanet.com/
